Long-term mortality after massive, submassive, and low-risk pulmonary embolism

被引:40
|
作者
Gupta, Rajesh [1 ,2 ]
Ammari, Zaid [2 ]
Dasa, Osama [2 ]
Ruzieh, Mohammed [2 ]
Burlen, Jordan J. [2 ]
Shunnar, Khaled M. [2 ]
Nguyen, Hanh T. [3 ]
Xie, Yanmei [3 ]
Brewster, Pamela [2 ]
Chen, Tian [3 ]
Aronow, Herbert D. [4 ]
Cooper, Christopher J. [1 ,2 ]
机构
[1] Univ Toledo, Coll Med & Life Sci, Div Cardiovasc Med, 3000 Arlington Ave,MS 1118, Toledo, OH 43614 USA
[2] Univ Toledo, Coll Med & Life Sci, Dept Med, Toledo, OH 43614 USA
[3] Univ Toledo, Dept Math & Stat, Toledo, OH 43614 USA
[4] Brown Univ, Warren Alpert Med Sch, Lifespan Cardiovasc Inst, Providence, RI 02912 USA
关键词
long-term outcome; mortality; pulmonary embolism (PE); risk stratification; submassive pulmonary embolism (PE); thrombosis; venous thromboembolism (VTE); DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; PROGNOSTIC VALUE; NORMOTENSIVE PATIENTS; CLINICAL PREDICTORS; EXTENDED TREATMENT; STRATIFICATION; RIVAROXABAN; PREVENTION; ASPIRIN;
D O I
10.1177/1358863X19886374
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Guidelines for management of normotensive patients with acute pulmonary embolism (PE) emphasize further risk stratification on the basis of right ventricular (RV) size and biomarkers of RV injury or strain; however, the prognostic importance of these factors on long-term mortality is not known. We performed a retrospective cohort study of subjects diagnosed with acute PE from 2010 to 2015 at a tertiary care academic medical center. The severity of initial PE presentation was categorized into three groups: massive, submassive, and low-risk PE. The primary endpoint of all-cause mortality was ascertained using the Centers for Disease Control National Death Index (CDC NDI). A total of 183 subjects were studied and their median follow-up was 4.1 years. The median age was 65 years. The 30-day mortality rate was 7.7% and the overall mortality rate through the end of follow-up was 40.4%. The overall mortality rates for massive, submassive, and low-risk PE were 71.4%, 44.5%, and 28.1%, respectively (p < 0.001). Landmark analysis using a 30-day cutpoint demonstrated that subjects presenting with submassive PE compared with low-risk PE had increased mortality during both the short- and the long-term periods. The most frequent causes of death were malignancy, cardiac disease, respiratory disease, and PE. Independent predictors of all-cause mortality were cancer at baseline, age, white blood cell count, diabetes mellitus, liver disease, female sex, and initial presentation with massive PE. In conclusion, the diagnosis of acute PE was associated with substantial long-term mortality. The severity of initial PE presentation was associated with both short- and long-term mortality.
引用
收藏
页码:141 / 149
页数:9
相关论文
共 50 条
  • [21] Long-term screening for pulmonary hypertension after pulmonary embolism
    Hogele, Jonas
    Gall, Henning
    Voswinckel, Robert
    Schulz, Richard
    Kemkes-Matthes, Beate
    Ghofani, Hossein A.
    Seeger, Werner
    Steiner, Dagmar
    Reichenberger, Frank
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [22] Cardiac Arrest Triage score best predicts mortality after intervention in patients with massive and submassive pulmonary embolism
    Hirai, Taishi
    Jones, DeShon
    Tate, Steven
    Dryer, Kathryn
    Churpek, Matthew
    Santiago, Lyn
    Edelson, Dana
    Friant, Janet
    Nathan, Sandeep
    Shah, Atman
    Paul, Jonathan
    Blair, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (18) : B319 - B320
  • [23] Short- and long-term mortality after pulmonary embolism in patients with and without cancer
    Alotaibi, Ghazi
    Wu, Cynthia
    Senthilselvan, Ambikaipakan
    McMurtry, Michael Sean
    VASCULAR MEDICINE, 2018, 23 (03) : 261 - 266
  • [24] Short- and long-term mortality after pulmonary embolism in patients with and without cancer
    Alotaibi, G.
    Wu, C.
    Senthilselvan, A.
    McMurtry, M. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 81 - 81
  • [25] TREATMENT FOR PULMONARY EMBOLISM IN A POPULATION WITH LOW-RISK SIMPLIFIED PULMONARY EMBOLISM
    Hamera, Joseph
    Talia, Nadine
    Sawyer, Kelly
    Berger, David
    CRITICAL CARE MEDICINE, 2020, 48
  • [26] Systemic Thrombolytic Therapy for Massive and Submassive Pulmonary Embolism
    Igneri, Lauren A.
    Hammer, John M.
    JOURNAL OF PHARMACY PRACTICE, 2020, 33 (01) : 74 - 89
  • [27] Management of Low-Risk Pulmonary Embolism Patients Without Hospitalization The Low-Risk Pulmonary Embolism Prospective Management Study
    Bledsoe, Joseph R.
    Woller, Scott C.
    Stevens, Scott M.
    Aston, Valerie
    Patten, Rich
    Allen, Todd
    Horne, Benjamin D.
    Dong, Lydia
    Lloyd, James
    Snow, Greg
    Madsen, Troy
    Elliott, C. Gregory
    CHEST, 2018, 154 (02) : 249 - 256
  • [28] LONG-TERM PROGNOSIS OF TREATED ACUTE MASSIVE PULMONARY-EMBOLISM
    HALL, RJC
    SUTTON, GC
    KERR, IH
    BRITISH HEART JOURNAL, 1977, 39 (10): : 1128 - 1134
  • [29] Systematic Review of Treatment for Massive and Submassive Pulmonary Embolism
    Gupta, Shipa
    Gandara, Esteban
    Carrier, Marc
    Castellucci, Lana A.
    BLOOD, 2016, 128 (22)
  • [30] Right Ventricular Responses to Massive and Submassive Pulmonary Embolism
    Castillo, Christian
    Tapson, Victor F.
    CARDIOLOGY CLINICS, 2012, 30 (02) : 233 - +